Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Membrane-Peptide Interactions : From Basics to Current Applications
| Membrane-Peptide Interactions : From Basics to Current Applications |
| Autore | Santos Nuno C |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 online resource (302 p.) |
| Soggetto topico |
Biology, life sciences
Research & information: general |
| Soggetto non controllato |
accelerated molecular dynamics
ACE inhibitory peptides alamethicin amino acid sequence anti-inflammatory peptide anti-metastatic activity anti-microbial peptides antibiofilm anticancer antimicrobial antimicrobial peptides atomic force microscopy bacterial membranes biofilm calcium hydroxide CD spectroscopy cell permeable peptide cell-penetrating peptide cell-penetrating peptides chemokine chionodracines circular dichroism circular dichroism spectroscopy collagen-induced arthritis critical aggregation concentration cyclin F cytotoxicity drug-peptide conjugates Enbrel ESKAPE pathogens feature selection glucosylceramide (GlcCer) heparin-binding peptide host defense peptide human beta defensin-3-C15 human dental pulp cell inducible nitric oxide interferon gamma interleukin-6 KR12 Langmuir monolayer lipid model systems lipopeptide liposomes LL-37 luffa sponge machine learning mass spectrometry Matrix-assisted laser desorption ionization melittin membrane membrane affinity membrane biophysics metastasis model of B16F10 melanoma model membranes molecular docking molecular dynamics mycolic acid NMR non-lytic peptides nuclear magnetic resonance solution structure organisms peptaibol peptide-lipid interaction peptide-lipid interactions peptide-membrane interaction phosphopeptide Pisum sativum defensin 1 (Psd1) pore-forming peptides sequence analysis sesame protein simulated gastrointestinal digestion solid-phase extraction Staphylococcus aureus Streptococcus gordonii lipoprotein structure-activity surface plasmon resonance tachyplesin |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
MembraneâPeptide Interactions
Membrane–Peptide Interactions |
| Record Nr. | UNINA-9910557551603321 |
Santos Nuno C
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide drug discovery and development [[electronic resource] ] : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos
| Peptide drug discovery and development [[electronic resource] ] : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2011 |
| Descrizione fisica | 1 online resource (392 p.) |
| Disciplina |
572.65
615.19 |
| Altri autori (Persone) |
CastanhoMiguel
SantosNuno C |
| Soggetto topico |
Peptide drugs
Drugs - Design Pharmacology |
| ISBN |
3-527-63674-9
1-283-30251-9 9786613302519 3-527-63673-0 3-527-63675-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptide Drug Discovery and Development: Translational Research in Academia and Industry; Contents; Preface; List of Contributors; Part I: The Academia - Market Bouncing of Peptide Drugs - Challenges and Strategies in Translational Research with Peptide Drugs; 1: Peptides as Leads for Drug Discovery; 1.1: Introduction; 1.2: Overview of Process for Transforming Peptides to Peptidomimetics; 1.3: HCMV Protease; 1.3.1: HCMV Protease: Identification and Characterization of Antiviral Inhibitors Targeting the Serine Protease Domain of the Human Cytomegalovirus (HCMV Protease)
1.3.2: Mapping Essential Elements of the Substrate Peptides and Determining Structures of Ligands Bound to HCMV1.3.3: Improving Peptide Activity to Allow SAR Studies; 1.3.4: Elucidation of the Binding Mode of the Optimized Peptidyl Segment; 1.3.5: Ligand Adaptations upon Binding; 1.3.6: Strategic Summary for HCMV Peptide Mimic Design Process; 1.4: HCV Protease; 1.4.1: HCV Protease as an Antiviral Target; 1.4.2: NS3 Serine Protease Possesses a Chymotrypsin-Like Fold; 1.4.3: Discovery of the Peptide DDIVPC as an Inhibitor of NS3 Protease 1.4.4: ''Sensemaking'' and Knowledge Building: Mapping of the Critical Binding Residues of the Peptide and Creation of an Inhibitor-Protease Model1.4.5: Knowledge Building: Monitoring Ligand Flexibility in the Free-State and Changes Upon Binding - P3 Rigidification; 1.4.6: N-Terminal Truncation and Improved P1, P2 and P5 Substituents; 1.4.7: Macrocyclization: Linking the Flexible P1 Side-Chain to P3; 1.4.8: HCV Protease Inhibitor BI00201335; 1.5: Herpes Simplex Virus; 1.5.1: Herpes Simplex Virus-Encoded Ribonucleotide Reductase Inhibitors; 1.6: Renin 1.6.1: Aspartyl Protease Renin as a Target1.7: HIV; 1.7.1: HIV Protease Inhibitors; 1.8: Conclusions; 2: Marketing Antimicrobial Peptides: A Critical Academic Point of View; 2.1: Introduction; 2.2: Basic Research: Antimicrobial Peptides; 2.3: Patents; 2.4: Potential Applications of AMPs; 2.5: Technology Transfer: Valorization, Licensing, or Spin-Off Creation; 2.6: Spin-Off Creation: An Academic Point of View; 3: Oral Peptide Drug Delivery: Strategies to Overcome Challenges; 3.1: Introduction; 3.2: Challenges Associated with Oral Peptide Delivery 3.2.1: Transport Pathways Across the Intestinal Epithelium3.2.2: Unfavorable Physicochemical Properties of Peptide Drugs; 3.2.2.1: Molecular Size, Hydrophilicity, and Physical Stability; 3.2.3: Physical Barriers of the Gastrointestinal Tract; 3.2.3.1: Transcellular Pathway; 3.2.3.2: Paracellular Pathway; 3.2.4: Biochemical Barriers of the Gastrointestinal Tract; 3.2.4.1: Luminal Enzymes; 3.2.4.2: Brush Border Membrane Bound Enzymes and Intracellular Enzymes; 3.2.5: Efflux Transport Systems; 3.2.6: Gastrointestinal Transit Time and Site-Specific Absorption 3.3: Strategies to Overcome the Barriers of the Gastrointestinal Tract |
| Record Nr. | UNINA-9910139579303321 |
| Weinheim, Germany, : Wiley-VCH, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide drug discovery and development : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos
| Peptide drug discovery and development : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2011 |
| Descrizione fisica | 1 online resource (xix, 370 pages) : illustrations |
| Disciplina |
572.65
615.19 |
| Altri autori (Persone) |
CastanhoMiguel
SantosNuno C |
| Soggetto topico |
Peptide drugs
Drugs - Design Pharmacology |
| ISBN |
9786613302519
9783527636747 3527636749 9781283302517 1283302519 9783527636730 3527636730 9783527636754 3527636757 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptide Drug Discovery and Development: Translational Research in Academia and Industry; Contents; Preface; List of Contributors; Part I: The Academia - Market Bouncing of Peptide Drugs - Challenges and Strategies in Translational Research with Peptide Drugs; 1: Peptides as Leads for Drug Discovery; 1.1: Introduction; 1.2: Overview of Process for Transforming Peptides to Peptidomimetics; 1.3: HCMV Protease; 1.3.1: HCMV Protease: Identification and Characterization of Antiviral Inhibitors Targeting the Serine Protease Domain of the Human Cytomegalovirus (HCMV Protease)
1.3.2: Mapping Essential Elements of the Substrate Peptides and Determining Structures of Ligands Bound to HCMV1.3.3: Improving Peptide Activity to Allow SAR Studies; 1.3.4: Elucidation of the Binding Mode of the Optimized Peptidyl Segment; 1.3.5: Ligand Adaptations upon Binding; 1.3.6: Strategic Summary for HCMV Peptide Mimic Design Process; 1.4: HCV Protease; 1.4.1: HCV Protease as an Antiviral Target; 1.4.2: NS3 Serine Protease Possesses a Chymotrypsin-Like Fold; 1.4.3: Discovery of the Peptide DDIVPC as an Inhibitor of NS3 Protease 1.4.4: ''Sensemaking'' and Knowledge Building: Mapping of the Critical Binding Residues of the Peptide and Creation of an Inhibitor-Protease Model1.4.5: Knowledge Building: Monitoring Ligand Flexibility in the Free-State and Changes Upon Binding - P3 Rigidification; 1.4.6: N-Terminal Truncation and Improved P1, P2 and P5 Substituents; 1.4.7: Macrocyclization: Linking the Flexible P1 Side-Chain to P3; 1.4.8: HCV Protease Inhibitor BI00201335; 1.5: Herpes Simplex Virus; 1.5.1: Herpes Simplex Virus-Encoded Ribonucleotide Reductase Inhibitors; 1.6: Renin 1.6.1: Aspartyl Protease Renin as a Target1.7: HIV; 1.7.1: HIV Protease Inhibitors; 1.8: Conclusions; 2: Marketing Antimicrobial Peptides: A Critical Academic Point of View; 2.1: Introduction; 2.2: Basic Research: Antimicrobial Peptides; 2.3: Patents; 2.4: Potential Applications of AMPs; 2.5: Technology Transfer: Valorization, Licensing, or Spin-Off Creation; 2.6: Spin-Off Creation: An Academic Point of View; 3: Oral Peptide Drug Delivery: Strategies to Overcome Challenges; 3.1: Introduction; 3.2: Challenges Associated with Oral Peptide Delivery 3.2.1: Transport Pathways Across the Intestinal Epithelium3.2.2: Unfavorable Physicochemical Properties of Peptide Drugs; 3.2.2.1: Molecular Size, Hydrophilicity, and Physical Stability; 3.2.3: Physical Barriers of the Gastrointestinal Tract; 3.2.3.1: Transcellular Pathway; 3.2.3.2: Paracellular Pathway; 3.2.4: Biochemical Barriers of the Gastrointestinal Tract; 3.2.4.1: Luminal Enzymes; 3.2.4.2: Brush Border Membrane Bound Enzymes and Intracellular Enzymes; 3.2.5: Efflux Transport Systems; 3.2.6: Gastrointestinal Transit Time and Site-Specific Absorption; 3.3: Strategies to Overcome the Barriers of the Gastrointestinal Tract |
| Record Nr. | UNINA-9910829074503321 |
| Weinheim, Germany, : Wiley-VCH, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||